Roche GLP-1R/GIPR agonist initiates phase III clinical trials
On January 20, 2026, according to the US Clinical Trial Registry website, Roche launched the first Phase II1 clinical trial of RO7795068 (CT-388).
GLP-1 Injections
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
(3)Capsule
(4)Injection
(5)Liquid Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
GLP-1 CAS 87805-34-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide GLP-1 Injections, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html
RO7795068 is a peptide GLP-1R/GIPR agonist developed by Carmot Therapeutics. In December 2023, Roche acquired Carmot Therapeutics for $3.1 billion, acquiring multiple intestinal insulinotropic drugs under the company's umbrella.
Phase I research data shows that among obese or overweight subjects without type 2 diabetes, RO7795068 can reduce their weight by 18.8% (adjusted by the placebo group) after 24 weeks of treatment, and the proportion of subjects whose weight loss is>5%,>10%, 15%, and>20% is 100%, 85%, 70%, and 45% respectively.
In obese or overweight subjects with type 2 diabetes, RO7795068 reduced the HbA1C level by 3.0% and body weight by 8.6% after 12 weeks of treatment.
The Phase I study launched this time is a randomized, double-blind, placebo-controlled clinical trial (n=1600) to evaluate the efficacy and safety of RO7795068 in treating obese or overweight patients with type 2 diabetes.
The main endpoint of the study was the percentage change in body weight at 72 weeks from baseline.
Geli's new generation GLP-1 triple target agonist ASC37 has launched clinical development and is planned to apply for IND approval in the United States
On January 20, 2026, Geli Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange code: 1672, abbreviated as "Geli") has selected the new generation of GLP-1R/GIPR/GCGR triple target agonist peptide ASC37 injection for subcutaneous administration once a month as a clinical development candidate drug. Geli is expected to submit an IND application for ASC37 injection for the treatment of obesity to the US Food and Drug Administration (FDA) in the second quarter of 2026.
ASC37 is a GLP-1R, GIPR, and GCGR triple target agonist peptide independently developed using the Artificial Intelligence assisted Structure Based Drug Discovery (ASBDD) and Ultra Long Acting Drug Development Platform (ULAP) technologies of Geli. Experimental results showed that ASC37 was on average about 5 times, 4 times, and 4 times stronger than retatrutide in terms of its excitatory activity towards GLP-1R, GIPR, and GCGR, respectively. Compared with the weekly administration of retatrutide, ASC37, which has been designed and optimized, achieves a longer observed half life (measured as the time required for blood drug concentration to drop to 50% of Cmax), thus supporting subcutaneous administration once a month with an injection volume not exceeding 1 milliliter. These optimized features enable lower scalability advantages in manufacturing for large-scale production.
Roche oral GLP-1 receptor agonist class 1 new drug approved for clinical use in China
On January 20, 2026, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that Roche's Class 1 new drug RO7795081 has been approved for clinical use in China and is intended for long-term weight management in overweight or obese patients. Public information shows that RO7795081 (CT-996) is an oral glucagon like peptide-1 (GLP-1) receptor agonist. RO7795081 (CT-996) is an oral small molecule GLP1R agonist originally developed by Carmot Corporation. At the end of 2023, Roche acquired Carmot for $3.1 billion, obtaining the latter's three clinical stage GLP-1 new drugs, including GLP-1/GIP dual receptor agonist CT-388, oral small molecule GLP-1 receptor agonist CT-996, and GLP-1/GIP dual receptor agonist CT-868
Tilpotide is planned to be included in breakthrough therapies for the treatment of metabolic associated fatty liver disease
On January 21, 2026, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Eli Lilly's GIP/GLP-1 dual receptor agonist, Puerpotide, is intended to be included in breakthrough therapy for the treatment of metabolic associated fatty liver disease.
In June 2024, Eli Lilly announced the detailed results of a Phase I SYNERGY-NASH study on the treatment of metabolic associated steatohepatitis (MASH) patients with cilapotide. This study included 190 subjects (with or without type 2 diabetes) with stage 2 or 3 fibrosis who were proved to be MASH by biopsy.
The effectiveness estimation targets showed that 51.85%, 62.8%, and 73.3% of subjects in the 5mg, 10mg, and 15mg groups of Puerpeptide, respectively, achieved complete remission of MASH in liver histology without worsening fibrosis after 52 weeks of treatment, while the proportion in the placebo group was 13.2%, achieving the primary endpoint of the study. This data will be presented at the 2024 Annual Meeting of the European Association for the Study of Liver Diseases (EASL) and also published in the New England Journal of Medicine (NEJM).
Jixing Pharmaceutical has completed a 2 billion yuan D1 round of financing to develop oral small molecule GLP-1 agonists
On January 22, 2026, in New Jersey, Corxel Pharmaceuticals Limited (Corxel), a clinical stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiovascular and metabolic diseases worldwide, announced the successful completion of its D1 round of funding, raising up to $287 million (RMB 2 billion). The proceeds from this round of financing are expected to support the development of CX11, also known as VCT220, a differentiated oral small molecule GLP-1 receptor agonist for obese and overweight patients. It is currently being evaluated in phase 2 trials at CORXEL in the United States and phase 3 trials at Vincentiage in China, as well as other cardiac metabolic projects, including acute ischemic stroke and hypertension. Jixing Pharmaceutical was incubated by RTW in 2019 and completed a $162 million Series D financing in 2024. Bayer and RTW invested $35 million and $127 million respectively in Jixing Pharmaceutical Technology (Shanghai) Co., Ltd.